SCHEMBL5369530

SCHEMBL5369530

Cc1c(Cl)cccc1NC(=S)NN=Cc1ccc(C(=O)O)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
GAA P10253 5/20 0.53
NPC1 O15118 4/20 0.53
KDM4E B2RXH2 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
RAB9A P51151 4/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.46
MAPK1 P28482 1/20 0.46
LMNA P02545 2/20 0.44
THRB P10828 1/20 0.44
HPGD P15428 1/20 0.44
RRM1 P23921 1/20 0.44
RRM2 P31350 1/20 0.44
RRM2B Q7LG56 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369527 1.00 MAPT (0.53) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL5364134 0.81 MAPT (0.53) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL5364129 0.81 MAPT (0.53) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL5365822 0.80 GAA (0.50) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL5365821 0.80 GAA (0.50) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL5364181 0.80 MAPT (0.54) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL5364183 0.80 MAPT (0.54) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL5373013 0.78 NCOA1 (0.55) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL5373019 0.78 NCOA1 (0.55) MAPTGAANPC1KDM4EL3MBTL1
SCHEMBL6130316 0.77 KDM4E (0.38) MAPTGAANPC1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885GAA 3120/4885NPC1 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.